Glucose production by the liver is essential for providing a substrate for the brain during fasting. The inability of insulin to suppress hepatic glucose output is a major aetiological factor in the hyperglycaemia of type-2 diabetes mellitus and other diseases of insulin resistance 1,2 . For fifty years, one of the few classes of therapeutics effective in reducing glucose production has been the biguanides, which include phenformin and metformin, the latter the most frequently prescribed drug for type-2 diabetes 3 . Nonetheless, the mechanism of action of biguanides remains imperfectly understood. The suggestion a decade ago that metformin reduces glucose synthesis through activation of the enzyme AMP-activated protein kinase (AMPK) has recently been challenged by genetic loss-of-function experiments 4 . Here we provide a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. In mouse hepatocytes, metformin leads to the accumulation of AMP and related nucleotides, which inhibit adenylate cyclase, reduce levels of cyclic AMP and protein kinase A (PKA) activity, abrogate phosphorylation of critical protein targets of PKA, and block glucagon-dependent glucose output from hepatocytes. These data support a mechanism of action for metformin involving antagonism of glucagon, and suggest an approach for the development of antidiabetic drugs.
Glucose production by the liver is essential for providing a substrate for the brain during fasting. The inability of insulin to suppress hepatic glucose output is a major aetiological factor in the hyperglycaemia of type-2 diabetes mellitus and other diseases of insulin resistance 1, 2 . For fifty years, one of the few classes of therapeutics effective in reducing glucose production has been the biguanides, which include phenformin and metformin, the latter the most frequently prescribed drug for type-2 diabetes 3 . Nonetheless, the mechanism of action of biguanides remains imperfectly understood. The suggestion a decade ago that metformin reduces glucose synthesis through activation of the enzyme AMP-activated protein kinase (AMPK) has recently been challenged by genetic loss-of-function experiments 4 . Here we provide a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. In mouse hepatocytes, metformin leads to the accumulation of AMP and related nucleotides, which inhibit adenylate cyclase, reduce levels of cyclic AMP and protein kinase A (PKA) activity, abrogate phosphorylation of critical protein targets of PKA, and block glucagon-dependent glucose output from hepatocytes. These data support a mechanism of action for metformin involving antagonism of glucagon, and suggest an approach for the development of antidiabetic drugs.
Biguanides exert their major effect through inhibition of liver glucose production, although enhanced glucose disposal has also been noted in some studies 5, 6 . Despite the wide acceptance of metformin as a first-line therapeutic for diabetes, its mechanism of action remains unclear. Metformin inhibits mitochondrial respiratory complex 1, thus reducing hepatic energy charge; ten years ago it was suggested that metformin functioned through activation of the kinase AMPK [7] [8] [9] [10] . This has been challenged recently in experiments using livers and primary hepatocytes lacking either AMPK or its upstream activating enzyme LKB1 (ref. 4). Because both glycogenolysis and gluconeogenesis are controlled during the fasting state in part by the hormone glucagon, the abnormal secretion of which is a major factor in the pathophysiology of hyperglycaemia in type-2 diabetes, we explored the idea that metformin produces its effects by inhibiting glucagon signalling pathways [11] [12] [13] .
Binding of glucagon to its receptor on the hepatocyte plasma membrane leads to activation of adenylyl cyclase, production of the second-messenger cyclic AMP (cAMP) and stimulation of PKA, which phosphorylates protein targets that work in concert to increase hepatic glucose output 12 . In primary mouse hepatocytes, we tested a panel of compounds that activate AMPK by decreasing energy charge or mimicking a reduced energy charge for the inhibition of glucagondependent increases in cAMP. Treatment with all agents increased AMPK phosphorylation and antagonized the glucagon-dependent elevation in cAMP ( Supplementary Fig. 1a, b ). Phenformin showed a dose-dependent inhibition of glucagon-induced cAMP accumulation with a half-maximal inhibitory concentration of ,150 mM, which correlated well with its effect on intracellular AMP (Fig. 1a, b ). To mimic more closely the chronic treatment of diabetic patients with biguanides, we tested 24-h exposure of hepatocytes to phenformin or metformin for a reduction in glucagon-increased cAMP levels. After long-term treatment, phenformin was effective at considerably lower concentrations, with concentrations of 10 mM or greater causing significant reductions in glucagon-stimulated increases in cAMP levels ( Fig. 1c ). Metformin also inhibited cAMP accumulation at concentrations of 125 mM or greater, levels slightly higher than in the serum of diabetic patients after taking a 1 mg dose of metformin but probably similar to those accumulated in splanchnic tissues 14, 15 (Fig. 1d ). In rats, administration of a therapeutic dose of 50 mg kg 21 leads to levels greater than 250 mM in the liver 14, 15 . Like phenformin, therapeutic concentrations of metformin elicited significant increases in AMP levels in primary hepatocytes ( Supplementary Fig. 2a -c). Glucagon did not alter adenine nucleotide levels or activate AMPK in primary hepatocytes and did not affect the changes produced by metformin ( Supplementary Fig. 2a-d) .
To determine the effects of phenformin on the kinetics of activation of PKA, we used the AKAR3 fluorescence resonance energy transfer (FRET) reporter 16 . Primary hepatocytes were infected with adenovirus encoding AKAR3 and 18 h later confocal images were acquired over time ( Supplementary Fig. 3a ). Glucagon increased the FRET ratio (FRET/cyan fluorescent protein (CFP)) of AKAR3 in the cytoplasm of hepatocytes within 1 min and reached a maximum at 2 min, thereafter exhibiting only minimal decay for 15 min. Phenformin both delayed the rise in PKA activity and accelerated its decay (Supplementary Fig. 3b ). The concentration dependence of inhibition of PKA activity measured biochemically was similar to blockade of cAMP accumulation in primary hepatocytes ( Fig. 1e ). AICAR, an adenosine analogue that can be phosphorylated to form the AMP mimetic ZMP, also antagonized the glucagon-dependent increase of PKA activity in isolated hepatocytes ( Supplementary Fig. 4a ).
Treatment of primary hepatocytes with phenformin inhibited the glucagon-dependent phosphorylation of cellular proteins at PKA substrate motifs (Fig. 1f ). Phenformin also antagonized phosphorylation of the PKA substrates PFKFB1 and the inositol-1,4,5-trisphosphate receptor IP3R (also known as ITPR1), as revealed by western blots using phospho-specific antibodies against these proteins ( Fig. 1f and Supplementary Fig. 5a ). If reductions in levels of endogenous cAMP are important for the actions of biguanides, we would expect the latter to block PKA target phosphorylation in response to glucagon but not a membrane-permeable analogue of cAMP, SP-8Br-cAMPS-AM. Glucagon induced phosphorylation of the PKA target proteins PFKFB1, CREB (also known as CREB1) and IP3R in primary hepatocytes; phenformin activated AMPK and inhibited phosphorylation of these PKA target proteins ( Fig. 2a and Supplementary Fig. 6a ). In contrast, when SP-8Br-cAMPS-AM concentrations were used that elicited comparable phosphorylation of the PKA substrates, the actions of SP-8Br-cAMPS-AM were not antagonized by phenformin ( Fig. 2b and Supplementary Fig. 6b ). These results demonstrate that phenformin inhibits the glucagon-but not SP-8Br-cAMPS-AM-dependent phosphorylation of PKA substrates, a result most consistent with biguanides working at a signalling step upstream from the activation of PKA. Both glucagon and SP-8Br-cAMPS-AM increased glucose output from primary hepatocytes; however, treatment of hepatocytes with therapeutic concentrations of metformin prevented glucagonbut not SP-8Br-cAMPS-AM-stimulated increases in glucose output ( Fig. 2b ). Of note, higher concentrations of metformin reduced basal as well as glucagon-and SP-8Br-cAMPS-AM-dependent glucose output. If the major actions of biguanide were mediated by decreases in cAMP, one would expect the drug to be ineffective in cells in which PKA has already been inhibited. In hepatocytes overexpressing a dominant-negative PKA regulatory subunit that is unable to bind cAMP, PKA activity was necessary for glucagon stimulation of glucose output, and biguanides did not reduce the rate of glucose output any further ( Supplementary Fig. 6c ).
As the biguanides and other drugs we used activated AMPK in parallel to the reduction in cAMP, we asked whether the kinase was required for the effects of biguanides. Mice homozygous for the floxed alleles of both catalytic a1 and a2 subunits of the AMPK complex were infected with adeno-associated virus expressing Cre recombinase, and western blots confirmed deletion of AMPK a protein and loss of phenformin-dependent phosphorylation of the AMPK substrate acetyl-CoA carboxylase (ACC) (Fig. 3a) . In hepatocytes lacking any detectable AMPK activity, phenformin blocked glucagon-dependent cAMP accumulation in a manner indistinguishable from that in control cells (Fig. 3b ). AICAR also reduced cAMP in the absence of AMPK ( Supplementary Fig. 4b ). These data show that the effects of biguanides on cAMP metabolism are independent of AMPK. 
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To determine whether reduction of the glucagon-dependent increase in cAMP was caused by activation of cAMP phosphodiesterase (PDE), we used pharmacological inhibitors of PDEs. If inhibition of cAMP degradation did not also block the effect of phenformin on cAMP, it would imply that the site of action was unlikely to be PDE. Exposure of glucagon-treated hepatocytes to 3-isobutyl-1methylxanthine (IBMX; a non-specific PDE inhibitor) or Ro-20-1724 (a specific PDE4 class inhibitor), but not cilostamide (a specific PDE3 class inhibitor), increased cAMP levels, indicating that PDE4 is the major cAMP-degrading enzyme in these cells ( Supplementary Fig. 7a ). Even in the presence of IBMX or Ro-20-1724, phenformin inhibited glucagon-stimulated accumulation of cAMP ( Supplementary Fig. 7a ). Moreover, Ro-20-1724 did not affect the dose responsiveness of hepatocytes to phenformin (Fig. 3c) . To resolve phenformin's site of action further, we measured its effects on cAMP accumulation in response to forskolin, which binds to and stimulates adenylyl cyclase independent of the activated Ga protein. Both phenformin and AICAR blocked cAMP accumulation by both glucagon and forskolin to the same extent, indicating that the effects of these drugs were unlikely to be due to modulation of the glucagon receptor or G-protein signalling ( Supplementary Figs 4c and 7b) .
As phenformin blocked glucagon-induced cAMP production at concentrations that correlated well with its effect on AMP levels, we sought to determine whether AMP could directly inhibit adenylyl cyclase, as has been reported previously [17] [18] [19] [20] . Forskolin and glucagon stimulated adenylyl cyclase activity about fourfold in membranes isolated from primary mouse hepatocytes ( Supplementary Fig. 8a ). AMP inhibited glucagon-stimulated adenylyl cyclase activity when ATP was present at 160 mM, which represents typical conditions for the assay, as well as at the more physiological concentration of 1.28 mM ATP (Fig. 3d ). To determine whether AMP accumulated in the livers of metformin-treated mice to levels sufficient to inhibit adenylyl cyclase, we measured hepatic AMP in fasted wild-type mice. Consistent with a recent report, we found the concentration of AMP to be 2.3 mM and to rise to 2.9 mM after treatment with metformin in mice fed a normal chow diet 21, 22 (Supplementary Table 1 ). Because these values seemed unphysiologically high, we also measured nucleotides in primary hepatocytes (Supplementary Table 2 ). In untreated cells, the AMP concentration was 215 mM, which correlated well with a value of 300 mM reported previously 23 in perfused rat liver using 31 P NMR. The AMP concentration in hepatocytes rose to over 1 mM in a dose-dependent manner upon treatment with phenformin (Supplementary Table 2 ).
To test whether the effects of biguanides on the accumulation of cAMP in primary hepatocytes were representative of its actions in vivo, we examined the effects of metformin after injection of glucagon into mice. Glucagon rapidly increased blood glucose, an effect that was blunted by pre-administration of metformin (Fig. 4a ). Gavage of mice with metformin increased both AMPK and ACC phosphorylation, indicating a decrease in the cellular energy charge of the liver ( Supplementary Fig. 9a ). Most importantly, metformin abrogated the subsequent glucagon-dependent increase in hepatic cAMP, PKA activity and phosphorylation of PKA substrates, demonstrating in vivo blockade of this pathway by biguanides (Fig. 4b, c) . To assess the effect of metformin on the action of endogenous glucagon, fasted mice were given an oral gavage of water or 250 mg kg 21 metformin, and 1 h later their blood glucose levels were determined and hepatic tissue was collected. This dose of metformin caused a significant drop in the blood glucose levels and an elevation in hepatic AMP (Supplementary Fig. 9b and Supplementary Table 1 ), which correlated well with a concomitant reduction in hepatic cAMP content ( Fig. 4d-f ). We next tested the effects of metformin in diabetic mice fed a high-fat diet (HFD) for 10 weeks. These mice had elevated fasting glucose levels and hepatic AMP compared to chow-fed animals (Supplementary a1/a2 lox/lox mice were infected with AAV-TBG-GFP or AAV-TBG-Cre virus and 14 days later primary hepatocytes were isolated. Cells were treated with the indicated concentrations of phenformin for 2 h followed by 5 nM glucagon or no treatment (NT) for 15 min. a, Total cellular protein was analysed by western blot for total (t) and phosphorylated (p) T172 AMPK and total and phospho-S79 ACC. b, Hepatocytes were lysed and total cellular cAMP levels were quantified by ELISA. N 5 4 for all points. c, Primary hepatocytes were incubated with the indicated concentrations of phenformin for 2 h and 50 mM RO-20-1724 (PDE4 inhibitor; PDE4i) for the final 30 min. Cells were then treated with 5 nM glucagon for 15 min, lysed, and total cellular cAMP was assayed. N 5 4 for all points. d, The membrane fraction of primary hepatocytes was isolated by differential centrifugation and used in assays for adenylyl cyclase activity in the presence of the indicated AMP and ATP concentrations, 100 nM glucagon and 100 mM GTP. N 5 6 for all points. Error bars represent s.e.m. Table 1 and Supplementary Fig. 10a, b ). Fasted HFD mice were given an oral gavage of water or 250 mg kg 21 metformin and 1 h later blood glucose was determined and hepatic tissue collected. Metformin significantly lowered blood glucose levels and elevated hepatic AMP ( Supplementary Fig. 10c and Supplementary Table 1 ). Importantly, treatment of these mice with metformin led to a reduction in the phosphorylation of two key PKA target proteins, PFKFB1 and the IP3R, and increased AMPK phosphorylation (Fig. 4g-i and Supplementary Fig. 10d ). The lack of change in Akt phosphorylation indicated that metformin was not affecting insulin responsiveness acutely ( Supplementary Fig. 10d, e ).
RESEARCH LETTER
Understanding the mechanism by which the drug metformin reduces hepatic glucose output is of considerable importance. Using a variety of biochemical and cell biological methods, we have confirmed earlier reports of an effect of biguanides on cAMP [24] [25] [26] [27] . Furthermore, we have shown that it is through an elevation in intracellular AMP that metformin substantially abrogates the activation of adenylyl cyclase by glucagon. This results in a reduction in the phosphorylation of key substrates for maintaining hepatic glucose output. For nearly 40 years it has been recognized that molecules containing an adenine moiety bind to the 'P site' of adenylyl cyclase and inhibit its activity 17 . Although the endogenous P-site ligand has been suggested to be AMP, the physiological or pharmacological relevance of this regulatory event has not previously been recognized [17] [18] [19] [20] 28 . We now provide support for the idea that therapeutic levels of metformin induce a mild energetic stress in hepatocytes, resulting in an increase in AMP concentration to levels capable of directly inhibiting adenylyl cyclase. These studies suggest that the P site of adenylate cyclase might represent a novel target for the development of therapeutics for the treatment of insulin resistance and type-2 diabetes.
METHODS SUMMARY
Primary hepatocytes were isolated by collagenase perfusion as described previously 29 . Adenine nucleotides were extracted from cells and liver with perchloric acid and measured by ion-pair reversed-phase (RP)-HPLC. cAMP in primary hepatocytes and frozen liver tissue was measured by ELISA (GE Healthcare) using the manufacturer's lysis buffer. PKA activity was assayed in cell lysates as PKI-sensitive Kemptide phosphorylation. PKA FRET-activity probes were used to examine intracellular PKA activity on a spinning-disc confocal microscope 16 . Adenylyl cyclase assays were performed using adenosine-59triphosphate [a-32 P] (American Radiolabelled Chemicals), and cAMP was quantified as previously described 30 . Glucose output studies in primary hepatocytes from fasted mice were carried out in Krebs buffer containing gluconeogenic substrates (20 mM lactate, 2 mM pyruvate, 10 mM glutamine) and were quantified using hexokinase-based glucose assays (Sigma). For in vivo experiments, metformin was gavaged at the indicated dosage and glucagon was injected intraperitoneally at the indicated dosages. Tissues were collected rapidly from anaesthetized mice and frozen in pre-cooled metal clamps. All results are expressed as the mean 6 s.e.m. All two-group comparisons were deemed statistically significant by unpaired two-tailed Student's t-test if P , 0.05. gavaged with 500 mg kg 21 metformin and 1 h later were injected intraperitoneally with 200 mg kg 21 glucagon, and glucose levels were measured at the indicated times. N 5 6 for water/PBS and metformin/glucagon, N 5 7 for water/glucagon and metformin/PBS. b, c, Fed mice were fasted for 1 h and gavaged with water or 500 mg kg 21 body weight of metformin. One-hour later mice were injected intraperitoneally with 2 mg kg 21 glucagon, and liver tissue was collected 5 min later. Liver was analysed for total hepatic cAMP by ELISA (b; N 5 3 for each group) and total hepatic PKA activity (c; N 5 7, 8, 6 and 7 for water/PBS, water/glucagon, metformin/PBS and metformin/glucagon, respectively). *P , 0.05 compared to PBS. d-f, 18-h fasted mice were gavaged with water or 250 mg kg 21 metformin, 1 h later liver tissue was collected, hepatic metabolites were extracted with perchloric acid and total hepatic AMP (d) and cAMP (e) levels were assayed. N 5 12 and 9 for the water and metformin groups, respectively. g-i, Mice fed HFD for 10 weeks were fasted overnight, gavaged with either water or 250 mg kg 21 metformin, and after 1 h liver tissue was collected for western blot analysis of the phosphorylation status of AMPK (g), PFKFB1 (h) and IP3R (i). N 5 3 for each group. Error bars represent s.e.m.
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